Drug adherence in patients taking oral anticoagulation therapy

Sebastian Ewen1, Volker Rettig-Ewen, Felix Mahfoud

  • 1Klinik für Innere Medizin III, Kardiologie, Angiologie und Internistische Intensivmedizin, Universitätsklinikum des Saarlandes, Kirrberger Str., Geb. 40, 66421, Homburg/Saar, Germany, Sebastian.Ewen@uks.eu.

Insights

Adherence to oral anticoagulation is crucial for preventing blood clots. This review explores factors impacting medication adherence and strategies to improve it for better patient outcomes.

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Patient Adherence Research

Background:

  • Oral anticoagulation therapy is vital for managing thromboembolic events, reducing mortality and morbidity.
  • Vitamin K antagonists (VKAs) present challenges including narrow therapeutic windows, drug-food interactions, and variable dosing, leading to risks of ineffective treatment or bleeding.
  • Direct oral anticoagulants (DOACs) offer comparable or superior efficacy and safety profiles to VKAs, with fixed dosing and no routine monitoring, simplifying management.

Purpose of the Study:

  • To review factors influencing medication adherence in patients undergoing oral anticoagulation.
  • To discuss strategies for enhancing drug adherence in patients prescribed oral anticoagulants.

Main Methods:

  • Literature review of studies on oral anticoagulation therapy.
  • Analysis of factors affecting patient adherence to anticoagulants.
  • Synthesis of strategies to improve medication adherence.

Main Results:

  • Adherence is a critical determinant of oral anticoagulation effectiveness and safety.
  • DOACs, while easier to use, present challenges in monitoring adherence.
  • Continuous and regular intake is essential for optimal therapeutic benefit.

Conclusions:

  • Understanding factors affecting adherence is key to optimizing oral anticoagulation therapy.
  • Implementing targeted strategies can improve medication adherence and patient outcomes.
  • Further research into adherence monitoring for DOACs is warranted.

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...